NCT04205799View on ClinicalTrials.gov

Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

January 15, 2023

Study Completion Date

January 15, 2023

Conditions
Advanced/Metastatic Cervical Cancer
Interventions
DRUG

Cabozantinib

Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.

Trial Locations (8)

Unknown

Institut de cancérologie de l'Ouest, Angers

Centre François Baclesse, Caen

Centre Oscar LAMBRET, Lille

Centre Léon Bérard, Lyon

Institut de Cancérologie de Montpellier, Montpellier

Institut de cancérologie de l'Ouest, Nantes

Institut CURIE, Saint-Cloud

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

Centre Francois Baclesse

OTHER

NCT04205799 - Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure | Biotech Hunter | Biotech Hunter